Inherited Pancreatic Cancer Syndromes and High-Risk Screening

Leah H Biller; Brian M Wolpin; Michael Goggins

doi:10.1016/j.soc.2021.06.002

Inherited Pancreatic Cancer Syndromes and High-Risk Screening

Surg Oncol Clin N Am. 2021 Oct;30(4):773-786. doi: 10.1016/j.soc.2021.06.002. Epub 2021 Jul 22.

Authors

Leah H Biller¹, Brian M Wolpin², Michael Goggins³

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Avenue, Boston, MA, USA. Electronic address: https://twitter.com/leahbillermd.
² Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Avenue, Boston, MA, USA. Electronic address: [email protected].
³ Johns Hopkins University, 1550 Orleans Street, Baltimore, MD, USA. Electronic address: [email protected].

Abstract

Pancreatic cancer is the third leading cause of cancer death in the United States, with a 5-year survival rate of 9%. Individuals with inherited pancreatic cancer syndromes are at an increased risk for developing pancreatic cancer and may benefit from pancreatic cancer surveillance with the goal to detect and intervene on early-stage cancer or high-risk precursor lesions. Given the screening implications for family members and therapeutic implications for probands, all patients diagnosed with pancreatic cancer are recommended to undergo germline genetic testing.

Keywords: Cancer risk; Hereditary; Pancreatic cyst; Surveillance.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Early Detection of Cancer
Genetic Predisposition to Disease
Humans
Neoplastic Syndromes, Hereditary* / diagnosis
Neoplastic Syndromes, Hereditary* / genetics
Pancreas
Pancreatic Neoplasms* / diagnosis
Pancreatic Neoplasms* / genetics
Risk Factors
United States

Abstract

Publication types

MeSH terms

Grants and funding